nodes	percent_of_prediction	percent_of_DWPC	metapath
Cefdinir—Interstitial lung disease—Mitoxantrone—lymphatic system cancer	0.0092	0.0092	CcSEcCtD
Cefdinir—Hepatic failure—Fludarabine—lymphatic system cancer	0.00884	0.00884	CcSEcCtD
Cefdinir—Agranulocytosis—Mechlorethamine—lymphatic system cancer	0.00881	0.00881	CcSEcCtD
Cefdinir—Haemoglobin—Mechlorethamine—lymphatic system cancer	0.00852	0.00852	CcSEcCtD
Cefdinir—Haemorrhage—Mechlorethamine—lymphatic system cancer	0.00848	0.00848	CcSEcCtD
Cefdinir—Cardiac failure—Fludarabine—lymphatic system cancer	0.00814	0.00814	CcSEcCtD
Cefdinir—Erythema multiforme—Mechlorethamine—lymphatic system cancer	0.00802	0.00802	CcSEcCtD
Cefdinir—Pancytopenia—Teniposide—lymphatic system cancer	0.00742	0.00742	CcSEcCtD
Cefdinir—Neutropenia—Teniposide—lymphatic system cancer	0.0073	0.0073	CcSEcCtD
Cefdinir—Toxic epidermal necrolysis—Fludarabine—lymphatic system cancer	0.00715	0.00715	CcSEcCtD
Cefdinir—Nephropathy—Methotrexate—lymphatic system cancer	0.00681	0.00681	CcSEcCtD
Cefdinir—Stomatitis—Teniposide—lymphatic system cancer	0.00679	0.00679	CcSEcCtD
Cefdinir—Interstitial pneumonia—Methotrexate—lymphatic system cancer	0.00671	0.00671	CcSEcCtD
Cefdinir—Candida infection—Carmustine—lymphatic system cancer	0.00668	0.00668	CcSEcCtD
Cefdinir—Leukocytoclastic vasculitis—Methotrexate—lymphatic system cancer	0.00661	0.00661	CcSEcCtD
Cefdinir—Leukopenia—Mechlorethamine—lymphatic system cancer	0.00661	0.00661	CcSEcCtD
Cefdinir—Pancytopenia—Fludarabine—lymphatic system cancer	0.00652	0.00652	CcSEcCtD
Cefdinir—Neutropenia—Fludarabine—lymphatic system cancer	0.00642	0.00642	CcSEcCtD
Cefdinir—Haemoglobin—Teniposide—lymphatic system cancer	0.00628	0.00628	CcSEcCtD
Cefdinir—Haemorrhage—Teniposide—lymphatic system cancer	0.00625	0.00625	CcSEcCtD
Cefdinir—Pneumonia—Fludarabine—lymphatic system cancer	0.00615	0.00615	CcSEcCtD
Cefdinir—Stevens-Johnson syndrome—Fludarabine—lymphatic system cancer	0.00607	0.00607	CcSEcCtD
Cefdinir—Acute coronary syndrome—Fludarabine—lymphatic system cancer	0.00603	0.00603	CcSEcCtD
Cefdinir—Anaphylactic shock—Mechlorethamine—lymphatic system cancer	0.00602	0.00602	CcSEcCtD
Cefdinir—Renal failure—Fludarabine—lymphatic system cancer	0.00602	0.00602	CcSEcCtD
Cefdinir—Myocardial infarction—Fludarabine—lymphatic system cancer	0.006	0.006	CcSEcCtD
Cefdinir—Stomatitis—Fludarabine—lymphatic system cancer	0.00596	0.00596	CcSEcCtD
Cefdinir—Thrombocytopenia—Mechlorethamine—lymphatic system cancer	0.0059	0.0059	CcSEcCtD
Cefdinir—Haematuria—Fludarabine—lymphatic system cancer	0.00583	0.00583	CcSEcCtD
Cefdinir—Anorexia—Mechlorethamine—lymphatic system cancer	0.00574	0.00574	CcSEcCtD
Cefdinir—Haemoglobin—Fludarabine—lymphatic system cancer	0.00552	0.00552	CcSEcCtD
Cefdinir—Haemorrhage—Fludarabine—lymphatic system cancer	0.00549	0.00549	CcSEcCtD
Cefdinir—Hepatic failure—Vincristine—lymphatic system cancer	0.0054	0.0054	CcSEcCtD
Cefdinir—Vaginal discharge—Methotrexate—lymphatic system cancer	0.00533	0.00533	CcSEcCtD
Cefdinir—Decreased appetite—Mechlorethamine—lymphatic system cancer	0.00524	0.00524	CcSEcCtD
Cefdinir—Erythema multiforme—Fludarabine—lymphatic system cancer	0.00519	0.00519	CcSEcCtD
Cefdinir—Renal failure acute—Mitoxantrone—lymphatic system cancer	0.00512	0.00512	CcSEcCtD
Cefdinir—Agitation—Teniposide—lymphatic system cancer	0.005	0.005	CcSEcCtD
Cefdinir—Leukopenia—Teniposide—lymphatic system cancer	0.00487	0.00487	CcSEcCtD
Cefdinir—Cardiac failure—Mitoxantrone—lymphatic system cancer	0.00484	0.00484	CcSEcCtD
Cefdinir—Pancytopenia—Bleomycin—lymphatic system cancer	0.00478	0.00478	CcSEcCtD
Cefdinir—Hypertension—Teniposide—lymphatic system cancer	0.0047	0.0047	CcSEcCtD
Cefdinir—Chest pain—Teniposide—lymphatic system cancer	0.00463	0.00463	CcSEcCtD
Cefdinir—Interstitial lung disease—Methotrexate—lymphatic system cancer	0.00458	0.00458	CcSEcCtD
Cefdinir—Pneumonia—Bleomycin—lymphatic system cancer	0.00451	0.00451	CcSEcCtD
Cefdinir—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00444	0.00444	CcSEcCtD
Cefdinir—Acute coronary syndrome—Bleomycin—lymphatic system cancer	0.00442	0.00442	CcSEcCtD
Cefdinir—Myocardial infarction—Bleomycin—lymphatic system cancer	0.0044	0.0044	CcSEcCtD
Cefdinir—Agitation—Fludarabine—lymphatic system cancer	0.00439	0.00439	CcSEcCtD
Cefdinir—Stomatitis—Bleomycin—lymphatic system cancer	0.00437	0.00437	CcSEcCtD
Cefdinir—Aspartate aminotransferase increased—Vincristine—lymphatic system cancer	0.00437	0.00437	CcSEcCtD
Cefdinir—Thrombocytopenia—Teniposide—lymphatic system cancer	0.00435	0.00435	CcSEcCtD
Cefdinir—Leukopenia—Fludarabine—lymphatic system cancer	0.00428	0.00428	CcSEcCtD
Cefdinir—Haematuria—Bleomycin—lymphatic system cancer	0.00428	0.00428	CcSEcCtD
Cefdinir—Pruritus—Mechlorethamine—lymphatic system cancer	0.00426	0.00426	CcSEcCtD
Cefdinir—Aspartate aminotransferase increased—Mitoxantrone—lymphatic system cancer	0.00425	0.00425	CcSEcCtD
Cefdinir—Anorexia—Teniposide—lymphatic system cancer	0.00423	0.00423	CcSEcCtD
Cefdinir—Pancytopenia—Carmustine—lymphatic system cancer	0.00417	0.00417	CcSEcCtD
Cefdinir—Convulsion—Fludarabine—lymphatic system cancer	0.00414	0.00414	CcSEcCtD
Cefdinir—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00412	0.00412	CcSEcCtD
Cefdinir—Neutropenia—Carmustine—lymphatic system cancer	0.00411	0.00411	CcSEcCtD
Cefdinir—Haemoglobin—Bleomycin—lymphatic system cancer	0.00405	0.00405	CcSEcCtD
Cefdinir—Haemorrhage—Bleomycin—lymphatic system cancer	0.00403	0.00403	CcSEcCtD
Cefdinir—Pancytopenia—Vincristine—lymphatic system cancer	0.00398	0.00398	CcSEcCtD
Cefdinir—Pneumonia—Carmustine—lymphatic system cancer	0.00394	0.00394	CcSEcCtD
Cefdinir—Neutropenia—Vincristine—lymphatic system cancer	0.00392	0.00392	CcSEcCtD
Cefdinir—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.0039	0.0039	CcSEcCtD
Cefdinir—Pancytopenia—Mitoxantrone—lymphatic system cancer	0.00388	0.00388	CcSEcCtD
Cefdinir—Decreased appetite—Teniposide—lymphatic system cancer	0.00386	0.00386	CcSEcCtD
Cefdinir—Renal failure—Carmustine—lymphatic system cancer	0.00385	0.00385	CcSEcCtD
Cefdinir—Vomiting—Mechlorethamine—lymphatic system cancer	0.00383	0.00383	CcSEcCtD
Cefdinir—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.00382	0.00382	CcSEcCtD
Cefdinir—Neutropenia—Mitoxantrone—lymphatic system cancer	0.00382	0.00382	CcSEcCtD
Cefdinir—Stomatitis—Carmustine—lymphatic system cancer	0.00382	0.00382	CcSEcCtD
Cefdinir—Rash—Mechlorethamine—lymphatic system cancer	0.0038	0.0038	CcSEcCtD
Cefdinir—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00379	0.00379	CcSEcCtD
Cefdinir—Pneumonia—Vincristine—lymphatic system cancer	0.00376	0.00376	CcSEcCtD
Cefdinir—Anorexia—Fludarabine—lymphatic system cancer	0.00372	0.00372	CcSEcCtD
Cefdinir—Acute coronary syndrome—Vincristine—lymphatic system cancer	0.00369	0.00369	CcSEcCtD
Cefdinir—Myocardial infarction—Vincristine—lymphatic system cancer	0.00366	0.00366	CcSEcCtD
Cefdinir—Pneumonia—Mitoxantrone—lymphatic system cancer	0.00366	0.00366	CcSEcCtD
Cefdinir—Stomatitis—Vincristine—lymphatic system cancer	0.00364	0.00364	CcSEcCtD
Cefdinir—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00363	0.00363	CcSEcCtD
Cefdinir—Acute coronary syndrome—Mitoxantrone—lymphatic system cancer	0.00359	0.00359	CcSEcCtD
Cefdinir—Renal failure—Mitoxantrone—lymphatic system cancer	0.00358	0.00358	CcSEcCtD
Cefdinir—Nausea—Mechlorethamine—lymphatic system cancer	0.00358	0.00358	CcSEcCtD
Cefdinir—Myocardial infarction—Mitoxantrone—lymphatic system cancer	0.00357	0.00357	CcSEcCtD
Cefdinir—Jaundice—Mitoxantrone—lymphatic system cancer	0.00355	0.00355	CcSEcCtD
Cefdinir—Stomatitis—Mitoxantrone—lymphatic system cancer	0.00355	0.00355	CcSEcCtD
Cefdinir—Conjunctivitis—Mitoxantrone—lymphatic system cancer	0.00354	0.00354	CcSEcCtD
Cefdinir—Haemoglobin—Carmustine—lymphatic system cancer	0.00353	0.00353	CcSEcCtD
Cefdinir—Haemorrhage—Carmustine—lymphatic system cancer	0.00352	0.00352	CcSEcCtD
Cefdinir—Body temperature increased—Teniposide—lymphatic system cancer	0.00351	0.00351	CcSEcCtD
Cefdinir—Abdominal pain—Teniposide—lymphatic system cancer	0.00351	0.00351	CcSEcCtD
Cefdinir—Haematuria—Mitoxantrone—lymphatic system cancer	0.00347	0.00347	CcSEcCtD
Cefdinir—Dyspepsia—Fludarabine—lymphatic system cancer	0.00344	0.00344	CcSEcCtD
Cefdinir—Agranulocytosis—Mitoxantrone—lymphatic system cancer	0.0034	0.0034	CcSEcCtD
Cefdinir—Decreased appetite—Fludarabine—lymphatic system cancer	0.00339	0.00339	CcSEcCtD
Cefdinir—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00337	0.00337	CcSEcCtD
Cefdinir—Constipation—Fludarabine—lymphatic system cancer	0.00334	0.00334	CcSEcCtD
Cefdinir—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.00328	0.00328	CcSEcCtD
Cefdinir—Hypersensitivity—Teniposide—lymphatic system cancer	0.00327	0.00327	CcSEcCtD
Cefdinir—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.00327	0.00327	CcSEcCtD
Cefdinir—Vaginal inflammation—Methotrexate—lymphatic system cancer	0.00324	0.00324	CcSEcCtD
Cefdinir—Asthenia—Teniposide—lymphatic system cancer	0.00319	0.00319	CcSEcCtD
Cefdinir—Melaena—Methotrexate—lymphatic system cancer	0.00317	0.00317	CcSEcCtD
Cefdinir—Pruritus—Teniposide—lymphatic system cancer	0.00314	0.00314	CcSEcCtD
Cefdinir—Leukopenia—Bleomycin—lymphatic system cancer	0.00314	0.00314	CcSEcCtD
Cefdinir—Body temperature increased—Fludarabine—lymphatic system cancer	0.00309	0.00309	CcSEcCtD
Cefdinir—Vaginal infection—Methotrexate—lymphatic system cancer	0.00306	0.00306	CcSEcCtD
Cefdinir—Aplastic anaemia—Methotrexate—lymphatic system cancer	0.00304	0.00304	CcSEcCtD
Cefdinir—Diarrhoea—Teniposide—lymphatic system cancer	0.00304	0.00304	CcSEcCtD
Cefdinir—Chest pain—Bleomycin—lymphatic system cancer	0.00298	0.00298	CcSEcCtD
Cefdinir—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00288	0.00288	CcSEcCtD
Cefdinir—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00286	0.00286	CcSEcCtD
Cefdinir—Vomiting—Teniposide—lymphatic system cancer	0.00282	0.00282	CcSEcCtD
Cefdinir—Agitation—Carmustine—lymphatic system cancer	0.00281	0.00281	CcSEcCtD
Cefdinir—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.0028	0.0028	CcSEcCtD
Cefdinir—Asthenia—Fludarabine—lymphatic system cancer	0.0028	0.0028	CcSEcCtD
Cefdinir—Rash—Teniposide—lymphatic system cancer	0.0028	0.0028	CcSEcCtD
Cefdinir—Dermatitis—Teniposide—lymphatic system cancer	0.0028	0.0028	CcSEcCtD
Cefdinir—Headache—Teniposide—lymphatic system cancer	0.00278	0.00278	CcSEcCtD
Cefdinir—Pruritus—Fludarabine—lymphatic system cancer	0.00276	0.00276	CcSEcCtD
Cefdinir—Leukopenia—Carmustine—lymphatic system cancer	0.00274	0.00274	CcSEcCtD
Cefdinir—Anorexia—Bleomycin—lymphatic system cancer	0.00273	0.00273	CcSEcCtD
Cefdinir—Agitation—Vincristine—lymphatic system cancer	0.00268	0.00268	CcSEcCtD
Cefdinir—Diarrhoea—Fludarabine—lymphatic system cancer	0.00267	0.00267	CcSEcCtD
Cefdinir—Convulsion—Carmustine—lymphatic system cancer	0.00265	0.00265	CcSEcCtD
Cefdinir—Hypertension—Carmustine—lymphatic system cancer	0.00264	0.00264	CcSEcCtD
Cefdinir—Nausea—Teniposide—lymphatic system cancer	0.00264	0.00264	CcSEcCtD
Cefdinir—Hepatic failure—Methotrexate—lymphatic system cancer	0.00262	0.00262	CcSEcCtD
Cefdinir—Leukopenia—Vincristine—lymphatic system cancer	0.00262	0.00262	CcSEcCtD
Cefdinir—Chest pain—Carmustine—lymphatic system cancer	0.00261	0.00261	CcSEcCtD
Cefdinir—Renal failure acute—Methotrexate—lymphatic system cancer	0.00255	0.00255	CcSEcCtD
Cefdinir—Leukopenia—Mitoxantrone—lymphatic system cancer	0.00255	0.00255	CcSEcCtD
Cefdinir—Convulsion—Vincristine—lymphatic system cancer	0.00253	0.00253	CcSEcCtD
Cefdinir—Hypertension—Vincristine—lymphatic system cancer	0.00252	0.00252	CcSEcCtD
Cefdinir—Dermatitis exfoliative—Methotrexate—lymphatic system cancer	0.00249	0.00249	CcSEcCtD
Cefdinir—Decreased appetite—Bleomycin—lymphatic system cancer	0.00249	0.00249	CcSEcCtD
Cefdinir—Vomiting—Fludarabine—lymphatic system cancer	0.00248	0.00248	CcSEcCtD
Cefdinir—Convulsion—Mitoxantrone—lymphatic system cancer	0.00247	0.00247	CcSEcCtD
Cefdinir—Rash—Fludarabine—lymphatic system cancer	0.00246	0.00246	CcSEcCtD
Cefdinir—Dermatitis—Fludarabine—lymphatic system cancer	0.00246	0.00246	CcSEcCtD
Cefdinir—Hypertension—Mitoxantrone—lymphatic system cancer	0.00246	0.00246	CcSEcCtD
Cefdinir—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00245	0.00245	CcSEcCtD
Cefdinir—Headache—Fludarabine—lymphatic system cancer	0.00244	0.00244	CcSEcCtD
Cefdinir—Chest pain—Mitoxantrone—lymphatic system cancer	0.00242	0.00242	CcSEcCtD
Cefdinir—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00238	0.00238	CcSEcCtD
Cefdinir—Anorexia—Carmustine—lymphatic system cancer	0.00238	0.00238	CcSEcCtD
Cefdinir—Thrombocytopenia—Vincristine—lymphatic system cancer	0.00233	0.00233	CcSEcCtD
Cefdinir—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00232	0.00232	CcSEcCtD
Cefdinir—Nausea—Fludarabine—lymphatic system cancer	0.00232	0.00232	CcSEcCtD
Cefdinir—Shock—Mitoxantrone—lymphatic system cancer	0.00228	0.00228	CcSEcCtD
Cefdinir—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00227	0.00227	CcSEcCtD
Cefdinir—Anorexia—Vincristine—lymphatic system cancer	0.00227	0.00227	CcSEcCtD
Cefdinir—Body temperature increased—Bleomycin—lymphatic system cancer	0.00226	0.00226	CcSEcCtD
Cefdinir—Insomnia—Carmustine—lymphatic system cancer	0.00226	0.00226	CcSEcCtD
Cefdinir—Somnolence—Carmustine—lymphatic system cancer	0.00222	0.00222	CcSEcCtD
Cefdinir—Anorexia—Mitoxantrone—lymphatic system cancer	0.00221	0.00221	CcSEcCtD
Cefdinir—Decreased appetite—Carmustine—lymphatic system cancer	0.00217	0.00217	CcSEcCtD
Cefdinir—Insomnia—Vincristine—lymphatic system cancer	0.00216	0.00216	CcSEcCtD
Cefdinir—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00216	0.00216	CcSEcCtD
Cefdinir—Constipation—Carmustine—lymphatic system cancer	0.00214	0.00214	CcSEcCtD
Cefdinir—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.00212	0.00212	CcSEcCtD
Cefdinir—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00211	0.00211	CcSEcCtD
Cefdinir—Decreased appetite—Vincristine—lymphatic system cancer	0.00207	0.00207	CcSEcCtD
Cefdinir—Somnolence—Mitoxantrone—lymphatic system cancer	0.00206	0.00206	CcSEcCtD
Cefdinir—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00206	0.00206	CcSEcCtD
Cefdinir—Asthenia—Bleomycin—lymphatic system cancer	0.00205	0.00205	CcSEcCtD
Cefdinir—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00204	0.00204	CcSEcCtD
Cefdinir—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00204	0.00204	CcSEcCtD
Cefdinir—Constipation—Vincristine—lymphatic system cancer	0.00204	0.00204	CcSEcCtD
Cefdinir—Asthma—Methotrexate—lymphatic system cancer	0.00203	0.00203	CcSEcCtD
Cefdinir—Pruritus—Bleomycin—lymphatic system cancer	0.00202	0.00202	CcSEcCtD
Cefdinir—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00202	0.00202	CcSEcCtD
Cefdinir—Constipation—Mitoxantrone—lymphatic system cancer	0.00199	0.00199	CcSEcCtD
Cefdinir—Abdominal pain—Carmustine—lymphatic system cancer	0.00197	0.00197	CcSEcCtD
Cefdinir—Body temperature increased—Carmustine—lymphatic system cancer	0.00197	0.00197	CcSEcCtD
Cefdinir—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00195	0.00195	CcSEcCtD
Cefdinir—Pancytopenia—Methotrexate—lymphatic system cancer	0.00193	0.00193	CcSEcCtD
Cefdinir—Neutropenia—Methotrexate—lymphatic system cancer	0.0019	0.0019	CcSEcCtD
Cefdinir—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.0019	0.0019	CcSEcCtD
Cefdinir—Abdominal pain—Vincristine—lymphatic system cancer	0.00188	0.00188	CcSEcCtD
Cefdinir—Body temperature increased—Vincristine—lymphatic system cancer	0.00188	0.00188	CcSEcCtD
Cefdinir—Hypersensitivity—Carmustine—lymphatic system cancer	0.00184	0.00184	CcSEcCtD
Cefdinir—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00184	0.00184	CcSEcCtD
Cefdinir—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00184	0.00184	CcSEcCtD
Cefdinir—Pneumonia—Methotrexate—lymphatic system cancer	0.00182	0.00182	CcSEcCtD
Cefdinir—Vomiting—Bleomycin—lymphatic system cancer	0.00182	0.00182	CcSEcCtD
Cefdinir—Rash—Bleomycin—lymphatic system cancer	0.0018	0.0018	CcSEcCtD
Cefdinir—Dermatitis—Bleomycin—lymphatic system cancer	0.0018	0.0018	CcSEcCtD
Cefdinir—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.0018	0.0018	CcSEcCtD
Cefdinir—Asthenia—Carmustine—lymphatic system cancer	0.00179	0.00179	CcSEcCtD
Cefdinir—Renal failure—Methotrexate—lymphatic system cancer	0.00178	0.00178	CcSEcCtD
Cefdinir—Stomatitis—Methotrexate—lymphatic system cancer	0.00177	0.00177	CcSEcCtD
Cefdinir—Conjunctivitis—Methotrexate—lymphatic system cancer	0.00176	0.00176	CcSEcCtD
Cefdinir—Hypersensitivity—Vincristine—lymphatic system cancer	0.00176	0.00176	CcSEcCtD
Cefdinir—Haematuria—Methotrexate—lymphatic system cancer	0.00173	0.00173	CcSEcCtD
Cefdinir—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00171	0.00171	CcSEcCtD
Cefdinir—Asthenia—Vincristine—lymphatic system cancer	0.00171	0.00171	CcSEcCtD
Cefdinir—Diarrhoea—Carmustine—lymphatic system cancer	0.00171	0.00171	CcSEcCtD
Cefdinir—Nausea—Bleomycin—lymphatic system cancer	0.0017	0.0017	CcSEcCtD
Cefdinir—Agranulocytosis—Methotrexate—lymphatic system cancer	0.00169	0.00169	CcSEcCtD
Cefdinir—Asthenia—Mitoxantrone—lymphatic system cancer	0.00167	0.00167	CcSEcCtD
Cefdinir—Dizziness—Carmustine—lymphatic system cancer	0.00165	0.00165	CcSEcCtD
Cefdinir—Haemoglobin—Methotrexate—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Cefdinir—Diarrhoea—Vincristine—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Cefdinir—Haemorrhage—Methotrexate—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Cefdinir—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Cefdinir—Vomiting—Carmustine—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Cefdinir—Dizziness—Vincristine—lymphatic system cancer	0.00158	0.00158	CcSEcCtD
Cefdinir—Rash—Carmustine—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Cefdinir—Dermatitis—Carmustine—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Cefdinir—Headache—Carmustine—lymphatic system cancer	0.00156	0.00156	CcSEcCtD
Cefdinir—Erythema multiforme—Methotrexate—lymphatic system cancer	0.00154	0.00154	CcSEcCtD
Cefdinir—Vomiting—Vincristine—lymphatic system cancer	0.00152	0.00152	CcSEcCtD
Cefdinir—Rash—Vincristine—lymphatic system cancer	0.0015	0.0015	CcSEcCtD
Cefdinir—Dermatitis—Vincristine—lymphatic system cancer	0.0015	0.0015	CcSEcCtD
Cefdinir—Headache—Vincristine—lymphatic system cancer	0.00149	0.00149	CcSEcCtD
Cefdinir—Nausea—Carmustine—lymphatic system cancer	0.00148	0.00148	CcSEcCtD
Cefdinir—Vomiting—Mitoxantrone—lymphatic system cancer	0.00148	0.00148	CcSEcCtD
Cefdinir—Rash—Mitoxantrone—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Cefdinir—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Cefdinir—Headache—Mitoxantrone—lymphatic system cancer	0.00145	0.00145	CcSEcCtD
Cefdinir—Nausea—Vincristine—lymphatic system cancer	0.00142	0.00142	CcSEcCtD
Cefdinir—Nausea—Mitoxantrone—lymphatic system cancer	0.00138	0.00138	CcSEcCtD
Cefdinir—Leukopenia—Methotrexate—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Cefdinir—Convulsion—Methotrexate—lymphatic system cancer	0.00123	0.00123	CcSEcCtD
Cefdinir—Chest pain—Methotrexate—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Cefdinir—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.00116	0.00116	CcSEcCtD
Cefdinir—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.00113	0.00113	CcSEcCtD
Cefdinir—Anorexia—Methotrexate—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Cefdinir—Insomnia—Methotrexate—lymphatic system cancer	0.00105	0.00105	CcSEcCtD
Cefdinir—Somnolence—Methotrexate—lymphatic system cancer	0.00103	0.00103	CcSEcCtD
Cefdinir—Dyspepsia—Methotrexate—lymphatic system cancer	0.00102	0.00102	CcSEcCtD
Cefdinir—Decreased appetite—Methotrexate—lymphatic system cancer	0.00101	0.00101	CcSEcCtD
Cefdinir—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000999	0.000999	CcSEcCtD
Cefdinir—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000946	0.000946	CcSEcCtD
Cefdinir—Abdominal pain—Methotrexate—lymphatic system cancer	0.000915	0.000915	CcSEcCtD
Cefdinir—Body temperature increased—Methotrexate—lymphatic system cancer	0.000915	0.000915	CcSEcCtD
Cefdinir—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000852	0.000852	CcSEcCtD
Cefdinir—Asthenia—Methotrexate—lymphatic system cancer	0.00083	0.00083	CcSEcCtD
Cefdinir—Pruritus—Methotrexate—lymphatic system cancer	0.000819	0.000819	CcSEcCtD
Cefdinir—Diarrhoea—Methotrexate—lymphatic system cancer	0.000792	0.000792	CcSEcCtD
Cefdinir—Dizziness—Methotrexate—lymphatic system cancer	0.000765	0.000765	CcSEcCtD
Cefdinir—Vomiting—Methotrexate—lymphatic system cancer	0.000736	0.000736	CcSEcCtD
Cefdinir—Rash—Methotrexate—lymphatic system cancer	0.000729	0.000729	CcSEcCtD
Cefdinir—Dermatitis—Methotrexate—lymphatic system cancer	0.000729	0.000729	CcSEcCtD
Cefdinir—Headache—Methotrexate—lymphatic system cancer	0.000725	0.000725	CcSEcCtD
Cefdinir—Nausea—Methotrexate—lymphatic system cancer	0.000687	0.000687	CcSEcCtD
